Halozyme Therapeutics (HALO) Free Cash Flow (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Free Cash Flow of $176.3 million for Q1 2026, up 15.05% year-over-year from $153.3 million in Q1 2025, and down 18.96% quarter-over-quarter from $217.6 million in Q4 2025.
Halozyme Therapeutics (HALO) Free Cash Flow (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Free Cash Flow for 17 consecutive years, with $176.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 15.05% year-over-year to $176.3 million; the TTM figure through Mar 2026 stood at $667.7 million (up 31.9% YoY), while the FY2025 annual figure was $644.6 million, up 34.63% from the prior year.
- Free Cash Flow declined to $176.3 million in Q1 2026 per HALO's latest filing, from $217.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $217.6 million in Q4 2025 and bottomed at $39.1 million in Q2 2022.
- Historically, Free Cash Flow has averaged $112.3 million across 5 years, with a median of $98.1 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 43.4% — and 2024, when it soared 112.15%.
- Halozyme Therapeutics' Free Cash Flow stood at $80.1 million in 2022, then increased by 9.34% to $87.6 million in 2023, then soared by 112.15% to $185.8 million in 2024, then advanced by 17.1% to $217.6 million in 2025, then dropped by 18.96% to $176.3 million in 2026.
- Business Quant data shows HALO's Free Cash Flow at $176.3 million in Q1 2026, $217.6 million in Q4 2025, and $175.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 236.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.72 Mn |
| Jun 30, 2026 | 236.72 Mn |
| Mar 31, 2026 | 176.34 Mn |
| Mar 31, 2026 | 176.34 Mn |
| Dec 31, 2025 | 217.60 Mn |
| Dec 31, 2025 | 217.60 Mn |
| Sep 30, 2025 | 175.57 Mn |
| Sep 30, 2025 | 175.57 Mn |
| Jun 30, 2025 | 98.15 Mn |
| Jun 30, 2025 | 98.15 Mn |
| Mar 31, 2025 | 153.27 Mn |
| Mar 31, 2025 | 153.27 Mn |
| Dec 31, 2024 | 185.83 Mn |
| Dec 31, 2024 | 185.83 Mn |
| Sep 30, 2024 | 108.23 Mn |
| Sep 30, 2024 | 108.23 Mn |
| Jun 30, 2024 | 58.84 Mn |
| Jun 30, 2024 | 58.84 Mn |
| Mar 31, 2024 | 125.88 Mn |
| Mar 31, 2024 | 125.88 Mn |